Biovie Inc (BIVI) - News Archive

BioVie s NE3107 Shows Promise for Improving Symptoms in Parkinson s Disease Patients and Potential Benefits for Alzheimer s Disease PatientsData from a Phase 2a trial conducted by BioVie Inc has demonstrated potential i...

NEW YORK, Feb. 17, 2024 Rosen Law Firm, a prominent global investor rights law firm, is encouraging investors who purchased securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021, and November 29, 2023, both da...

BIOVIE INC. FACES CLASS ACTION LAWSUIT FOR SECURITIES FRAUDBiovie Inc., a major player in the pharmaceutical preparations industry, finds itself in hot water as a class action lawsuit has been filed against the company...

New York, Jan. 23, 2024 - Rosen Law Firm, a prominent investor rights law firm, has recently filed a class action lawsuit on behalf of BioVie Inc. (NASDAQ: BIVI) investors who purchased securities between August 5, 2021...

BioVie Inc., a biopharmaceutical company focused on developing innovative therapies for serious neurological diseases, recently released encouraging efficacy data from a Phase 3 clinical trial of NE3107 in patients with...